|
|
 |
|
Viewing report
|
|
|
|
World Pharmacovigilance Markets in Lifesciences
Frost & Sullivan, Dec 2008, Pages: 83
World Pharmacovigilance Markets presents an all-encompassing research of Pharmacovigilance markets for three regions: North America, Europe and Japan. The research focuses on end user spending in various segments of Pharmacovigilance. The challenges to manage drug safety efficiently and to adhere to regulatory requirements have dictated the need for cutting edge Pharmacovigilance tools and technologies.
This Frost & Sullivan research service titled World Pharmacovigilance Markets in Lifesciences provides total market forecasts for three regions – North America, Europe and Japan – in terms of end-user spending and adoption rates. In this research, Frost & Sullivan's expert analysts thoroughly examine the following technologies: drug safety database systems and signal detection systems.
Outsourcing/Offshoring Environment Offers Considerable Potential for Pharmacovigilance Market
The challenge to manage adverse events in an optimal and efficient way and, at the same time, adhere to regulatory requirements has dictated the need for cutting edge pharmacovigilance tools and technologies.
“Regulatory bodies such as the Food & Drug Administration (FDA) and EMEA are intensifying safety regulations, thereby boosting the adoption rates of pharmacovigilance systems by pharmaceutical companies,” notes the analyst of this research. “The need to operate in a cost-effective way is inducing pharmaceutical companies to outsource/offshore their pharmacovigilance operations.” For large companies, the volume of adverse events is sizeable. Even a product from a mid-size company can generate a high volume of adverse events. There is significant potential for outsourcing/offhsoring for mid-sized companies as well.
Most top pharmaceutical companies have well-established systems and processes. Consequently, they are not willing to replace these systems as this entails high costs and is also time consuming. Moreover, the migration of data from one system to another tends to be expensive for most companies. Aligning existing processes to fit in the new system is difficult.
Vendors should educate pharmaceutical companies about technology implications and its importance in their day-to-day operations. This will be necessary to overcoming prevailing skepticism about new technology and its merits. They should conduct seminars and conferences to trigger interest and make pharmaceutical companies understand that technology that functions optimally can offer substantial return on investments (ROI).
“There will be advances in data integration that will support more flexible decision making on drug safety issues,” remarks the analyst. “There is significant scope to extend pharmacovigilance systems to boost their integration with a range of other data sources such as medical records and clinical data.”
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
